TNYA News and Press, Tenaya Therapeutics Inc. From 01/09/23

Phase 1b Clinical Trial for TN-201 in MYBPC3-associated HCM Patients Expected to Begin Dosing in Third Quarter 2023; Data Anticipated in 2024 Data from First-in-Human Clinical Trial of TN-301 Anticipated in Second Half 2023 TN-401 IND Submission Planned in Second Half 2023 ...

SOUTH SAN FRANCISCO, Calif., Dec. 07, 2022 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (Nasdaq: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced the a...

What Are The Best Penny Stocks To Buy Right Now? The 2022 stock market crash has weighed heavily on retail traders. Whether trading penny stocks or stocks over $100, this year has been a tough one to navigate if you’re a “buy and hold” investor. But the outcomes are l...

What Are The Best Penny Stocks To Buy Right Now? November is winding down, but that hasn’t stopped the flow of funds into penny stocks . Even with the stock market down today, traders and investors are hunting for new opportunities to buy the dip, trade the trend, or simply m...

TN-401 is being developed for the treatment of genetic arrhythmogenic right ventricular cardiomyopathy (ARVC) caused by mutations in the PKP2 gene Orphan Drug Designation for TN-401 is the first for a gene therapy treatment for ARVC Expect to submit TN-401 IND applicatio...

SOUTH SAN FRANCISCO, Calif., Nov. 23, 2022 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced...

SOUTH SAN FRANCISCO, Calif., Nov. 21, 2022 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (Nasdaq: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, announced today...

Tenaya Therapeutics ( NASDAQ: TNYA ) shares are down 19.4% after-hours after the firm has priced its underwritten public offering of 22,613,307 shares of its common stock at a price of $2.60/share and, to certain investors in lieu of common stock, pre-funded warrants to pu...

SOUTH SAN FRANCISCO, Calif., Nov. 17, 2022 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (Nasdaq: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced...

Tenaya Therapeutics ( NASDAQ: TNYA ) said on Wednesday it will offer and sell $75M shares of common stock in an underwritten public offering. Tenaya intends to grant the underwriters a 30-day option to purchase up to an additional $11.25M of shares of its common stock at t...